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Abstract
3% of the population develops saccular intracranial aneurysms (sIAs), a complex trait, with a sporadic and a familial form.
Subarachnoid hemorrhage from sIA (sIA-SAH) is a devastating form of stroke. Certain rare genetic variants are enriched in the
Finns, a population isolate with a small founder population and bottleneck events. As the sIA-SAH incidence in Finland is.26
increased, such variants may associate with sIA in the Finnish population. We tested 9.4 million variants for association in 760
Finnish sIA patients (enriched for familial sIA), and in 2,513 matched controls with case-control status and with the number of
sIAs. The most promising loci (p,5E-6) were replicated in 858 Finnish sIA patients and 4,048 controls. The frequencies and
effect sizes of the replicated variants were compared to a continental European population using 717 Dutch cases and 3,004
controls. We discovered four new high-risk loci with low frequency lead variants. Three were associated with the case-control
status: 2q23.3 (MAF 2.1%, OR 1.89, p 1.42610-9); 5q31.3 (MAF 2.7%, OR 1.66, p 3.17610-8); 6q24.2 (MAF 2.6%, OR 1.87, p
1.87610-11) and one with the number of sIAs: 7p22.1 (MAF 3.3%, RR 1.59, p 6.086-9). Two of the associations (5q31.3, 6q24.2)
replicated in the Dutch sample. The 7p22.1 locus was strongly differentiated; the lead variant was more frequent in Finland
(4.6%) than in the Netherlands (0.3%). Additionally, we replicated a previously inconclusive locus on 2q33.1 in all samples
tested (OR 1.27, p 1.87610-12). The five loci explain 2.1% of the sIA heritability in Finland, and may relate to, but not explain,
the increased incidence of sIA-SAH in Finland. This study illustrates the utility of population isolates, familial enrichment, dense
genotype imputation and alternate phenotyping in search for variants associated with complex diseases.
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Introduction
About 3% of the population develops saccular intracranial
aneurysms (sIAs) during life [1,2]. Some 95% of subarachnoid
hemorrhages are caused by ruptured sIA (sIA-SAH), a devastating
form of stroke affecting individuals mainly in the sixth decade of
life [3]. The annual incidence of SAH is 4–9 per 100 000
worldwide [4] but over twice as high in Finland and in Japan [5].
The sIA disease is a complex trait, the risk of which is affected by
age, sex, smoking, hypertension, excess drinking [6], and in over
10% of the cases family history of sIA disease [7–9].
To date, genome wide association (GWA) studies have identified
six definite and one probable loci with common variants associated
to sIA: 4q31.23 (OR 1.22) [10,11]; 8q11.23–q12.1 (OR 1.28);
9p21.3 (OR 1.31); 10q24.32 (OR 1.29); 12q22 (OR 1.16) [10];
13q13.1 (OR 1.20); 18q11.2 (OR 1.22) [12] (Table S5). These
seven loci were estimated to explain 6.1%, 4.4% and 4.1% of the
four-fold sibling recurrence risk in Finland, Europe and Japan
respectively [10]. In these previous GWA studies, results on 2q33.1
locus were inconsistent: the locus was significant in the first GWAS
[13], not significant in the enlarged follow-up GWAS [12], and in
the third GWAS the risk allele was reversed in the Japanese
replication sample [10].
The population of Finland is one of the most thoroughly
characterized genetic isolates. Due to the small size of the founder
population, subsequent bottleneck effects and genetic drift, the
Finnish population is enriched for rare and low frequency variants
that are almost absent in other European populations and some
variants rare elsewhere are increased in frequency [14]. This is
best illustrated by the increased prevalence of 36 rare Mendelian,
mostly recessive, disorders in Finland (www.findis.org); the so
called Finnish disease heritage (FDH) [15]. We hypothesized that
some of the enriched rare or low frequency variants could
contribute to the increased sIA-SAH susceptibility in Finland.
In this GWA study we combined the power of 1000 Genomes
imputation, the special benefits of a population isolate and
enrichment of familial cases in the discovery cohort. Familial sIA
patients more often carry multiple sIAs as compared to sporadic
sIA patients, which may confer additional genetic burden to the
sIA formation [8,16,17]. Therefore, in addition to the case vs.
control analysis, we also analyzed the number of sIAs per
individual as an intermediate phenotype. We conducted an
association analysis in a discovery sample of 760 Finnish sIA
cases and 2,513 matched controls followed by replication in an
additional sample of 858 Finnish sIA cases and 4048 controls. The
successfully replicated loci in Finland were further studied in a
Dutch cohort of 717 sIA cases and 3004 controls to assess the
extent to which the allele frequencies and risk effect sizes match
between the isolate of Finland and a continental European
population (Figure 1). In addition, we hypothesized that a
previously inconclusive locus on 2q33.1 [10,13,18] is a true sIA
risk locus at least in Finland and aimed to replicate the best
discovery associations in the locus in this study in the Finnish and
in the Dutch samples.
We successfully identified associations with low frequency
variants in three novel loci in the case vs. control analysis and
one in the aneurysm count analysis. Two of the case vs. control
loci replicated also in the Dutch cohort with similar allele
frequencies and comparable risk effect sizes. The variant in the
aneurysm count locus demonstrated a strong bottleneck effect by
being 15 times more frequent in the Finnish than in the Dutch
controls. We also successfully replicated the previously inconclu-
sive 2q33.1 locus.
Results
Case vs. control analysis in Finnish and Dutch samples
To increase the potential genetic load in the study sample, our
discovery sample consisted of 760 cases from the isolated, high-risk
Finnish population, purposefully enriched for familial sIA (40%)
patients and 2513 genetically matched Finnish controls. The
imputation of the 304,399 previously genotyped variants [12]
against the 1000 Genomes Project reference panel (v3, March
2012 release) increased the number of common and low frequency
variants available for the association analysis to 9,359,231.
Quantile-quantile (QQ) plots of association p-values did not
indicate substantial inflation (l=1.04) (Figure S1). The discovery
association analysis revealed one locus at 12p11.1 driven by
rs653464 at conventional genome-wide significance (p,561028)
and 14 other loci at p,561026 (Table S1; Manhattan plot in
Figure S3).
We chose 17 SNPs representing the 15 promising loci (p,
561026) above for replication in an independent sample of 858
Finnish sIA cases and 4,048 controls (Table 1). Four SNPs and one
deletion were associated at p,0.05 with the sIA disease (Table S1),
two of them in the previously reported sIA loci 9p21.3 (rs1333042;
OR 1.3, p= 6.361027) and 13q13.1 (rs113124623; OR 0.88,
p = 0.01). The genome-wide significant 12p11.1 locus in the
discovery sample did not replicate (p = 0.29).
In the meta-analysis of the two Finnish samples, four SNPs
reached the commonly used level of genome-wide significance at
p,561028 (Table 2). Three were novel: 2q23.3 (rs74972714; OR
2.1, 95% CI 1.68–2.63, p= 7.4610211, control allele frequency or
CAF 2.35%), 5q31.3 (rs113816216; OR 1.92, CI 1.53–2.40,
p = 1.7461028, CAF 2.09%) and 6q24.2 (rs75018213; OR 1.97,
CI 1.6–2.43, p= 2.25610210, CAF 2.53%). One was previously
reported at 9p21.3 (rs1333042; OR 1.31, CI 1.21–1.42,
p = 1.8610211, CAF 42.3%) (Table 2). We assessed the robustness
of the associations controlling also for age and the effect sizes and
p-values were almost identical (data not shown).
To assess how the allele frequencies and effect sizes of variants
identified in the Finnish population compare to other European
populations, we studied those variants in a Dutch sample
consisting of 717 sIA cases and 3,004 controls (Table 1). All three
variants tagging the novel loci at 2q23.3, 5q31.3 and 6q24.2 had a
similar low minor allele frequency (1.6–3.9%) in Finland and the
Netherlands (Table 2). Two of them had similar effect sizes and
were also replicated: 5q31.3 (rs113816216; OR 1.3, CI 0.98–1.75,
p = 0.045, CAF 3.87%) and 6q24.2 (rs75018213; OR 1.5, CI
0.98–2.3 p= 0.034, CAF 2.3%). The previously reported 9p21.3
locus also replicated in the Dutch sample (rs1333042; OR 1.32, CI
1.17–1.49, p = 3.4261026, CAF 47.86%).
In the meta-analysis of the Finnish and Dutch samples, all three
novel loci 2q23.3 (rs74972714; OR 1.89, p = 1.4261029), 5q31.3
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(rs113816216; OR 1.66, p = 3.1761028) and 6q24.2 (rs75018213;
1.87, p = 7.1610211) were significantly associated to the sIA
disease at genome-wide significance (Table 2; see Table S7 for
imputation accuracy statistics). Some heterogeneity in effect sizes
exists between samples (Table S9).
As the standard genome-wide significance 561028 is estimated
to correct for independent tests of common variants (MAF.=5%)
and we tested also a set of low-frequency variants, the common
significance level may be too liberal. Based on Europeans of the
1000 Genomes project we estimated the significance level to be
3.8261028 (See Materials and Methods). All of the reported
variants are below this level.
Association of variants to the number of sIAs
Some 20–30% of the sIA patients carry multiple sIAs, a
phenomenon more commonly seen in familial sIA disease
[8,16,17]. We hypothesized that an increased number of sIAs ($
2) in a given patient would reflect a higher underlying genetic load,
motivating us to use aneurysm count as an intermediate phenotype
to increase statistical power. The number of sIAs was used as a
count data using the negative binomial regression analysis in the
discovery sample of 760 Finnish sIA cases (1–8 sIAs per patient)
and 2,513 controls. The QQ plot (Figure S2) and the genomic
inflation factor (1.05) did not indicate substantial population
stratification.
Nine loci had variants at p,5E-6 (Table S2; Manhattan plot in
Figure S4). The most significant variant of each locus was selected
for replication in the new Finnish sample of 858 sIA cases (1–6
sIAs per patient) and 4,048 controls. Two loci were replicated at
p,0.05: 7p22.1 (rs150927513; RR 1.39, p = 8.3661024, CAF
5.24%) and 16p13.3 (rs144159053; rate ratio (RR) 1.66,
p = 4.461023, CAF 1.27%) (Table S2). rs10802056 on 1p12 had
a significant association p-value but the effect direction was
different and thus was not considered as replicated. We assessed
the robustness of the associations controlling also for age and the
effect sizes and p-values were almost identical (data not shown).
Author Summary
Genome-wide association studies (GWAS) have been
extensively used to identify common genetic variants
associated with complex diseases. As common genetic
variants have explained only a small fraction of the
heritability of most complex diseases, there is a growing
interest in the role of how low frequency and rare variants
contribute to the susceptibility. Low frequency variants are
more often specific to populations of distinct ancestries.
Saccular intracranial aneurysms (sIA) are balloon-like
dilatations in the arteries on the surface of the brain. The
rupture of sIA causes life-threatening intracranial bleeding.
sIA is a complex disease, which is known to sometimes run
in families. Here, we utilize the recent advancements in
knowledge of genetic variation in different populations to
examine the role of low-frequency variants in sIA disease in
the isolated population of Finland where sIA related
strokes are more common than in most other populations.
By studying .8000 Finns we identify four low-frequency
variants associated with the sIA disease. We also show that
the association of two of the variants are seen in other
European populations as well. Our findings demonstrate
that multiple study designs are needed to uncover more
comprehensively their genetic background, including
population isolates.
Figure 1. Study design. The Finnish discovery and replication cohorts represent a population with over two-fold increased risk of subarachnoid
hemorrhage from ruptured saccular intracranial aneurysm (sIA-SAH). The Finnish discovery cohort was intentionally enriched with familial sIA
patients, and 9.4M genotyped and imputed variants were studied. The loci with p,5E-6 were replicated in an independent and unselected Finnish
sIA sample. The allele frequencies and effect sizes of the replicated variants in Finland were finally compared to continental European population
using a Dutch sample. The sIA-SAH risk is not increased in the Netherlands (‘general risk’ in the figure).
doi:10.1371/journal.pgen.1004134.g001
Low Frequency Intracranial Aneurysm Risk Variants
PLOS Genetics | www.plosgenetics.org 3 January 2014 | Volume 10 | Issue 1 | e1004134
In the meta-analysis of the Finnish samples, 7p22.1 was
genome-wide significant (rs150927513; RR 1.6, CI 1.37–1.88,
p = 4.9261029, CAF 4.61%);Table 3; See genotype to aneurysm
count distribution in Table S3). The rate ratio (RR) estimate is the
relative rate of aneurysm formation (i.e. change in expected
number of aneurysms) per allele as compared to minor allele
homozygotes.
To compare the allele frequency and effect size of rs150927513
identified in the Finnish population to those of continental
European populations, we studied the variant also in the Dutch,
but the imputation quality (Impute info 0.38) and estimated allele
frequency (0.29%) were too low to obtain reliable estimates (RR
0.97; 95% CI 0.17–4.03, p = 0.97). We additionally checked the
minor allele frequency of rs150927513 in 498 whole-genome
sequenced Dutch individuals of GENOMEoftheNETHER-
LANDS-project (http://www.nlgenome.nl/). Only two individuals
were heterozygous and the rest were major allele homozygotes
(MAF 0.2%), which is in agreement with our imputation results of
the Dutch sample.
Analysis of 2q33.1 locus
Previously published results on the 2q33.1 locus are inconsis-
tent, being significant in the first GWAS [13], not significant in
the enlarged follow-up GWAS [12], and uncertain in the third
GWAS [10]. We aimed to study if the 2q33.1 would replicate in
Finland, even though no variant in this region reached p,5E-6
in the discovery sample. We chose two of the most significant
SNPs (in this study) at 2q33.1 for replication in the new Finnish
replication sample, which was not used in the previous studies
(rs12472355; OR 1.21, p = 2.2361024, CAF 44.3%, and
rs919433; OR 1.18, p = 1.0161023, CAF 44.6%). They are in
LD with the three previously investigated SNPs (rs787994,
rs1429412, rs700651; LD r2 0.75–0.96). The variants
rs12472355 (OR 1.23, CI 1.13–1.33, p = 4.8461027) and
rs919433 (OR 1.21, CI 1.12–1.31, p = 2.1561026) did not reach
genome-wide significance in the combined Finnish samples
(Table 2). They were highly significant in the Dutch sample
(rs12472355; OR, 1.39, CI 1.23–1.57, p = 1.0561027 and
rs919433; OR 1.43, CI 1.26–1.61, p 9.7761029), and in the
meta-analysis of all three samples they reached genome-wide
significance (Table 2). The allele frequencies were notably higher
in the Finnish samples (44% and 43.7%) than in the Dutch
samples (33.2% and 31%).
Heritability estimate
We estimated the heritability explained by the reported
variants. The four novel loci on 2q23.3, 5q31.3, 6q24.2 and
7p22.1 were estimated to explain 1.7% of the heritability in the
combined Finnish samples. Adding the previously inconclusive
2q33.1 locus increases the heritability explained to 2.1%.
Genotype validation
For validating the imputation accuracy, we genotyped 87
individuals of the discovery sample using Sequenom genotyping.
The concordance rates range from 96–99% except rs74972714
was slightly lower at 94% (Table S8). We did additional validation
by Sanger sequencing 10 individuals per variant who were
predicted to carry minor alleles. The imputation was near perfect
in all other SNPs except rs75018213 had discrepancies between
major allele homozygote and heterozygotes (Table S11). We
further estimated by simulation, how likely it would be to get the
observed OR for rs75018213 in the discovery sample just by
change, given the imputation accuracy (See Text S1 for details).
The probability of chance finding was very low (p: 0.0001) even if
assuming that the minor allele would be over-imputed by 20% in
cases (p: 0.004).
Some individuals were genotyped by both Sanger sequencing
and Sequenom and the concordance between the two methods
was perfect (Table S11). Finally, we estimated, in silico, the
imputation efficiency of reported SNPs in Dutch population. 96
individuals of the Genome of the Netherlands project had both
high coverage whole-genome sequencing (406) data as well as
GWA chip genotyping data available. We imputed the genotypes
of reported SNPs using the same imputation methods, 1000
Genomes reference panel and set of SNPs in GWA chips as was
done in the discovery and Dutch comparison analyses. The
genotype concordance rates were excellent (Table S13). It is
noteworthy that the imputation quality measure reported by the
Impute2 program was higher in all of the SNPs in our Dutch
replication cohort (Table S7) than in the in silico validation
experiment. This indicates excellent imputation quality in the
Dutch replication.
Fine mapping of the identified loci
We attempted to identify putative causative variants from whole
exome sequencing data of 583 Finnish individuals. We focused on
variants within 1 MB of the lead SNPs with high impact on
Table 1. The Finnish and Dutch study samples used in the association analysis of saccular intracranial aneurysm (sIA) disease.
Finnish discovery Finnish replication Dutch replication
Cases Controls Cases Controls Cases Controls
N 760 2,513 858 4,048 717 3,004
Women 443 (58%) 1,454 (58%) 532 (62%) 2,182 (54%) 492 (67%) 1,135 (38%)
Familial sIA 300 (40%) - 51 (6%) - 100 (15%)* -
sIA-SAH 561 (74%) - 587 (68%) - 658 (92%) -
Mean age (SD) 50 (12.6) 56 (13) 52 (12.2) 40 (9.95) 54 (11.7) 68 (10.44)
Number of sIAs
Mean (range) 1.54 (1–8) - 1.46 (1–6) - 1.26 (1–7) -
$2 242 (32%) - 257 (30%) - 127 (18%)** -
*Unknown familial sIA status for 35 patients.
**Number of sIAs not known for 16 patients.
SD = Standard deviation.
doi:10.1371/journal.pgen.1004134.t001
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protein product (i.e. variants affecting splice site, losing or gaining
stop/start codon, altering reading frame) or non-synonymous
coding SNPs. We additionally filtered variants if they were not in
LD with the lead SNPs (r2,0.4, Europeans of 1000 Genomes if
available). 254 variants were identified, most of which were rare.
However 15 variants were enriched to low-frequency range
(MAF.1%) (Table S12). The impact of these variants needs to be
evaluated in follow-up studies.
Regulatory elements at identified loci
The UCSC Genome Browser and HaploReg version 2 [19]
were used to search for ENCODE regulatory elements at the five
genome-wide significant variants.
rs74972714 at 2q23.3 and rs150927513 at 7p22.1 reside within
a DNAse hypersensitivity peak. The rs75018213 at 6q24.2 resides
on an ENCODE GATA2 transcription factor binding site peak
(Table S4).
Using genome-wide Chip-SEQ analysis, Ernst et al. constructed
a predicted cell-type specific regulatory region map of nine
chromatin marks in nine cell lines [20]. rs113816216 at 5q31.3
resides on a predicted erythroleukemia cell specific (K562) strong
enhancer and rs75018213 at 6q24.2 on a predicted lymphoblas-
toid cell (GM12878) weak enhancer (Table S4).
We searched for putative transcription factor binding sites
affected by the four variants, based on position weight matrices
from Transfac, Jaspar and ENCODE (top 3 enriched motifs for
each transcription factor, identified in transcription factor Chip-
SEQ peaks [19]). rs74972714 at 2q23.3 affects putative binding
sites for EBF1 (ENCODE), HDAC2 (ENCODE), RXRA:PPARG
complex (Transfac), ZNF423 (Jaspar) and ZIC3 (Jaspar).
rs113816216 at 5q31.3 affects the putative binding sites for
RFX1 (Transfac), SREBP1 (ENCODE), STAT3 (Transfac) and
IKZF3 (Transfac). rs150927513 at 7p22.1 affects putative binding
sites of T (brachyury) (Transfac), CEBPB (Transfac) and P300
(ENCODE). rs75018213 at 6q24.2 is not directly on any putative
transcription factor binding site. (Table S4).
At the 2q33.1 locus neither of the studied variants (rs919433,
rs12472355) are on ENCODE DNAse hypersensitivity or
transcription factor binding site peaks. However, rs919433 is on
a predicted lymphoblastoid (GM12878) cell enhancer whereas
rs12472355 is not directly on any regulatory region. rs919433
disrupts a putative transcription factor binding sites for RUNX2
(OSF2,Transfac) and the MYC:MAX complex (Transfac).
eQTL analysis
To study the potential effects of the variants in the five
significant loci on the transcripts of nearby genes, we correlated
the variants to expression levels of exons of nearby genes
(expression quantitative trait locus (eQTL) analysis) obtained
using RNA-sequencing in lymphoblasts of genotyped European
individuals from the 1000 Genomes Project (Finnish, British,
Toscani and CEPH populations, n = 373; www.geuvadis.org,
[21]). Each variant was correlated to transcripts residing within
1 MB. There were 55 genes in 586 exons available for analysis (see
Materials and Methods) and in total 748 tests were performed
corresponding to Bonferroni corrected significance threshold of
8.761025. Strongest association for each variant are reported
below and all eQTL results in Table S6.
The most significant eQTL associations were observed at the
2q33.1 locus: rs12472355 associated significantly to the closest
gene ANKRD44 (per allele fold change (FC) 0.94, p= 1.8361025)
and also to HSPD1 (FC 0.94, p= 1.661024), whereas rs919433
was associated to the same genes but in different order of
significance; HSPD1 (FC 0.94, p= 3.861025) and ANKRD44 (FC
0.95, p = 1.461024). Among the novel low-frequency variants,
only rs150927513 at 7p22.1 was significantly associated to
TNRC18 (FC 1.23, p = 5.161025). Nominal associations were
observed for two other novel low frequency variants: rs113816216
at 5q31.3 to VDAC1 (FC 2.12, p 4.6E-4); rs74972714 at 2q23.3 to
EPC2 (FC 0.75, p = 3.961022). rs75018213 at 6q24.2 did not have
any association even at nominal p,0.05 (Table S6).
We additionally investigated the eQTL landscape of identified
loci by pairwise comparison of p-values from eQTL (MAF.0.05
p,0.001) and sIA analyses (Figure S5) and by plotting eQTL
associations (p,0.001) in the implicated loci (Supplementary
Figure S6 A–E). Only few loci show strong (p,1E-5) association in
eQTL and at least nominal (p,0.05) association to sIA (Table
S10). There does not seem to be stronger eQTL associations in LD
with the lead SNPs. In the 2q33.1, where the lead SNPs were
significantly associated to transcript levels, there seems to be a lot
of regulatory potential in the same locus, even though not in direct
LD with the lead variants (Figure S6 E).
Discussion
In this study, we used three approaches to improve the power to
identify new loci associated to the sIA disease. First, we focused on
the Finnish population isolate with increased risk for subarachnoid
haemorrhage from ruptured sIAs (sIA-SAH) [5]. Second, we
enriched the proportion of familial sIA patients in the discovery
sample, thus possibly increasing the prevalence of risk alleles.
Third, we increased genome-wide coverage through imputing
ungenotyped variants based on 1000 Genomes Project data. The
used 1000 Genomes Project imputation reference panel included
93 Finns, which made it well suited for discovery of enriched sIA
associated variants in the Finnish population. Using this combi-
nation of strategies, we were able to identify three new loci
associated with sIA disease, and one locus associated with the
number of aneurysms. Additionally we replicated a locus where
the evidence so far was inconclusive. Together these five loci
account for 2.1% of the heritability in the Finnish samples. In
comparison, the six previously identified SNPs explain 2.5% of the
heritability in the discovery sample of the current study. Our
results likely reflect the varying genetic background of complex
traits, such as sIA, in different populations.
Four novel sIA loci
The lead SNPs in the four novel loci all have a low frequency (,
5%) in the general population and could not have been identified
without imputing the genotype data against the 1000 Genomes
reference. One of the variants, rs150927513 at 7p22.1 that was
associated with the number of sIAs, indicates a strong bottleneck
effect, for it was 15 times more frequent in the controls of
combined Finnish samples (4.6%) than in the Dutch sample
(0.3%), and it is virtually non-existent in other populations (1000
Genomes). The three other loci had similar frequencies in Finland
and other European populations (1000 Genomes). These four
novel loci explain 1.7% of the heritability in the Finnish samples.
The four sIA loci had higher effect sizes (point estimates ranging
from 1.59 to 1.88) than the lead SNPs identified by previous GWA
studies. We cannot yet conclude whether relatively high ORs of
low frequency risk alleles are a typical feature of sIA disease.
Similar, and higher, odds ratios for low frequency and rare
variants have been reported in isolates for other traits [22,23]. It is
likely that this first wave of low frequency and rare susceptibility
variants represent ‘‘low hanging’’ fruits that do not allow general
conclusions about the susceptibility landscape of sIA or other
complex traits.
Low Frequency Intracranial Aneurysm Risk Variants
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2q23.3 locus
The variant rs74972714 at 2q23.3 has a frequency of about 2%
in European populations, including Finns. It was significantly
associated to sIA in the Finnish samples but did not show a trend
for being associated in the Dutch sample despite having a similar
allele frequency. Further studies are required to find out whether
this variant tags a risk allele specific to Finnish sIA patients. The
variant is located 40 kb downstream of LYPD6 and 55 kb
upstream of MMADHC (Figure 2 A). LYPD6 has recently been
characterized as a member of the Ly-6 protein superfamily [24].
LYPD6 is ubiquitously expressed with highest levels in heart and
brain. GPI-anchored Ly-6 proteins such as PLAUR function, e.g.,
in cellular adhesion [24]. LYPD6 overexpression can inhibit
transcriptional activity of the AP1 transcription factor complex
[24], a key inflammation mediator activated, e.g., in endothelial
cells in atherogenic disturbed blood flow conditions, leading in
turn to upregulation of pro-inflammatory molecules [25]. Similar
transcriptional changes have been found in the ruptured human
sIA wall [26].MMADHC is an intracellular vitamin B12 trafficking
gene. Mutations in this gene can cause methylmalonic aciduria or
homocystinuria, or both [27].
5q31.1 locus
The variant rs113816216 at 5q31.3 has a frequency of 1–3% in
Finland and most other European populations, except in Spain
(7%). It was significantly associated to the sIA disease in the
Finnish samples and was also significant in the Dutch sample but
had a somewhat lower OR there (Table 2). The meta-analysis of
all combined samples exceeded the genome wide significance
threshold. The variant is located in the intron of FSTL4 (Figure 2
B), a poorly characterized gene. FSTL1, a paralog of FSTL4, codes
a protein inducing innate immunity as TLR4 agonist [28].
Increased tissue levels of FSTL1 were associated to the severity
of heart failure [29] and to the coronary artery aneurysm
formation in Kawasaki disease [30]. Variants in FSTL4 were
modestly associated to human ischemic stroke [31], and a variant
70 kb from FSTL4 nominally to hypertension [32].
6q24.2 locus
The variant rs75018213 at 6q24.2 has similar frequencies (2%)
in European populations, including Finns. It was significantly
associated to the sIA disease in the Finnish samples and was
also significant in the Dutch sample but had a somewhat
lower OR there (Table 2). It is located in the intron of EPM2A.
The LD spans over 300 kb downstream covering FBXO30,
LOC100507557, SHPRH and GRM1 (Figure 2 C). In the
ENCODE data, rs75018213 is located in a GATA2 transcription
factor binding site RNA-seq peak. Homozygous deletions in the
EPM2A gene result in progressive myoclonus epilepsy (PME)
with Lafora bodies (OMIM 254780) [33]. No vascular anomalies
have been reported in EPM2 deletion patients with a PME
phenotype or their heterozygote parents. EPM2A encodes a
phosphatase, which dephosphorylates glycogen, but it is likely
that EPM2A has broader functions in regulation of glycogen
biosynthesis, endoplasmic reticulum stress, autophagy, and
possibly also cell cycle [34].
7p22.1 locus and the number of sIAs
The variant rs150927513 at 7p22.1 was significantly associated
to sIA count per individual in the Finnish population (Table 1). Its
frequency was 4.6% in the Finnish samples but only 0.3%, in the
Dutch sample, in line with most European populations. This
variant would therefore likely not have been identified if a
sufficient number of Finnish individuals had not been included in
the reference panel.
The variant is located in the intron of RADIL (Figure 2 D), a rap
GTPase interactor, an essential effector of RAP1 in activation of
integrins in cell-adhesive signalling by G protein-coupled receptors
[35]. RADIL has also been shown to control, together with RAP1,
neutrophil adhesion and chemotaxis [36]. Neutrophils seem to
have a role in the formation and rupture of intracranial and
abdominal aortic aneurysm [26,37,38]. The strongest eQTL
association was to an exon of TNRC18 (FC 1.23, p = 5.161025), a
functionally uncharacterized gene.
As we analysed the number of sIAs as a count variable from 0–
8, the inherent assumption was that the same variant would
increase the risk of the first and the subsequent sIA formation.
Thus, any variant associated to the number of sIAs will to some
extent be associated in the case vs. control analysis. Indeed, in the
analysis of combined Finnish cohorts rs150927513 was associated
in the case-control analysis (OR 1.54, p = 6.561027) and
consistently also in the analysis of multiple vs. single sIA patients
(OR 1.65, p = 8.461024). The association of this variant, should
be interpreted as reflecting the tendency of sIA formation, rather
than considering multiple sIAs as a completely different dichot-
omous end point.
Previously identified 9p21.3 locus
The 9p21.3 locus has been robustly associated to the sIA disease
[12] as well as to cardiovascular, metabolic and cancer traits
[39,40], and it has been extensively studied by others [41]. The
allele frequency and effect size in the current study, although with
a different lead SNP (r2 = 0.7 to previous lead SNP rs1333040), are
in strong agreement with the previous study [12]. This locus is not
therefore discussed further here.
2q33.1 locus with previously inconclusive evidence
Two common variants, rs12472355 and rs919433 at 2q33.1
were significantly associated to the sIA disease in the Finnish and
Dutch samples (Table 2), rs919433 intronic and rs12472355
upstream 30 kb from ANKRD44 (Figure 2 E). The allele
frequencies were somewhat higher in the Finnish samples
(rs919433, 44%; rs12472355 43.7%) than in the Dutch samples
(33.2%; 31%) or in the Japanese population according to 1000
Genomes Project (28.1%; 27.5%). In this locus, the risk allele was
reversed in the Japanese cohort of the previous sIA GWA study
[10]. ANKRD44 is likely a subunit of protein phosphatase 6 [42]
that functions, e.g., in cell cycle control [43] and in inhibition of
NF-kB activation [44]. NF-kB is a significant mediator in
experimental sIA formation in rats, highly expressed in human
sIA wall [45], and it was associated to human sIA wall rupture in
transcriptomic profiling [26]. In eQTL analysis rs12472355 was
significantly associated to ANKRD44 (FC 0.94, p = 1.8361025) and
rs919433 to HSPD1 (FC 0.94, p = 3.861025)
In conclusion, we identified four novel loci associated to sIA
disease and confirmed one additional locus with previously
inconclusive evidence, together explaining 2.1% of the sIA
heritability in Finland. Our data illustrates the utility of high-risk
population isolates, familial disease history, and dense genotype
imputation in search for low-frequency variants associated to
complex human diseases. The inclusion of Finnish individuals in
the imputation reference panel and especially the highly differen-
tiated variant in 7p22.1 would likely not have been identified
The identification of the four novel low frequency variants
would likely have required much larger sample sizes in more
mixed populations. Further studies of the identified five loci are
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Figure 2. Regional association plots of the five identified saccular intracranial aneurysm (sIA) loci in the combined Finnish samples
and the Dutch sample. Association p-values (2log10 scale, y-axis) of variants are shown according to their chromosomal positions (x-axis). Blue
lines indicate the genetic recombination rate (cM/Mb). Figures A–C present the loci identified in the case vs. control analysis at 2q23.3, 5q31.3, and
6q24.2, respectively. Figure D presents the 7p22.1 locus associated to the sIA count per patient. Figure E presents the 2q33.1 locus with inconclusive
previous evidence. Purple rectangles indicate the most significant variant in a) the Finnish discovery sample and, along the dashed line, its p-values in
b) the combined Finnish samples (META FIN) and in c) all samples (META ALL). Adjacent variants in linkage disequilibrium (r2; EUR populations, 1000
Genomes March 2012) to the index variant are shown in colours indicating their r2 levels (r2 box in each figure).
doi:10.1371/journal.pgen.1004134.g002
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needed to explain their functional mechanisms in the pathogenesis
of sIA disease.
Materials and Methods
Ethics statement
For all of the Finnish and Dutch samples, the local ethics
committees approved the study and all patients gave written
informed consent.
Study samples
A. Finnish discovery sample. The initial discovery GWAS
data consisted of previously Illumina genotyped 974 Finnish
intracranial aneurysm patients and 740 controls [12]. The patients
were collected from the registries of Neurosurgery, Kuopio
University Hospital, and Neurosurgery, Helsinki University
Hospital, solely serving their catchment populations in Eastern
and Southern Finland, respectively. The sIAs were angiograph-
ically verified and the cases of subarachnoid hemorrhage from
ruptured sIA (sIA-SAH) with computed tomography (CT).
Patients with at least 1 first-degree relative carrying sIA disease
were considered familial [8]. For the unruptured aneurysms we do
not have the exact indications for these patients available.
However in our aneurysm database in Neurosurgery of Kuopio
University Hospital the indications for angiography of unruptured
aneurysm patients were: 1) Incidental unruptured sIA (leading
cause was headache) found in neuroimaging with non-related
indications 383/467=83% 2) Incidential unruptured sIA found in
neuroimaging screening of sIA family members 45/467= 9.6%
and 3) Symptomatic but unruptured sIA causing focal neurological
symptoms 39/467= 8.4%
The Helsinki Birth Cohort Study (HBCS) includes 8,760
individuals born in the Helsinki Central Hospital between 1934
and 1944 [46]. A subset of 1676 Illumina genotyped individuals
were available for the present study. The Health 2000 Cohort
(H2000) includes 2 402 Finns, and of those 2138 Illumina
genotyped individuals were available for the present study [47,48].
The discovery aneurysm cases, 740 population controls and
Health 2000 controls have been used in the previous sIA GWA
studies [10,12].
The following 210 cases and 119 controls were removed from
the discovery sample: fusiform aneurysm carriers (n = 5); dupli-
cated cases (n = 9) and controls (n = 10); blind duplicate cases
(n = 15) and controls (n = 5); genotyping rate ,97% (29 cases, 31
controls); individuals with higher missingness from cryptically
related pairs (Identity by descent (IBD).0.1875, similarity halfway
between 2nd and 3rd degree relatives: 69 cases, 55 controls);
genetic distance to 5 nearest neighbours .4 standard deviations
longer than the average distance (2 cases, 18 controls); patients not
traceable from the database or with traumatic SAH (n= 81);
polycystic kidney disease (n = 4).
The following SNPs were removed: missing genotypes .5%;
minor allele frequency ,1%; Hardy-Weinberg disequilibrium p-
value in controls ,1*10-6; symmetric SNPs (A/T, C/G); and
SNPs not on all the genotyping platforms.
To minimize false positives, each sIA case was matched to three
controls by gender and genetic distance from control individuals.
First, a sliding window approach was used to thin the set of SNPs
to be approximately independent of each other. A sliding window
of 1500 SNPs was shifted by 150 SNPs at a time along
chromosomes, and in each step SNPs were filtered if any pairwise
r2 was .0.2, resulting in 79596 independent SNPs. Pairwise IBS
distances of these SNPs were used in multidimensional scaling and
four first dimensions were used in matching. Plink v. 1.07 [49] was
used for thinning and MDS analysis. R package optmatch was
used to pair each case to three controls. After 1:3 matching,
additionally all Eastern Finnish controls from the previous sIA
study were included [12].
The final discovery sample consisted of 760 sIA cases and 2,513
controls (Table 1). After SNP filtering, there were 304,399
genotyped SNPs and 9,046,433 imputed SNPs and indels (see
imputation paragraph for imputation QC) for the discovery
sample.
B. Finnish replication sample. The replication sample
consisted of 858 independent sIA patients from the registry of
Neurosurgery, Kuopio University Hospital. There were 1,605
independent controls, 453 from Eastern Finland and 1152 from
the FINRISK study, both genotyped using the Sequenom iPLEX
technique. Additionally, 2,443 whole genome genotyped controls
from The Cardiovascular Risk in Young Finns Study were
acquired and replication SNPs were extracted after imputation
(Table 1).
The Cardiovascular Risk in Young Finns Study is a follow-up
study of cardiovascular risk factors from childhood to adulthood
[50,51]. The participants were randomly chosen from the Finnish
Population Registry and recruited from five university cities in
Finland. The baseline study launched in 1980 and included 3,596
individuals. Follow-ups have taken place at every three to six years
with the last one in 2007 at 27 years of age.
The FINRISK cohort is a national survey on risk factors of
chronic and non-communicable diseases in Finland [52]. The
survey has been conducted every five years since 1972 in randomly
selected, representative population samples from different parts of
Finland.
C. Dutch replication sample. The Dutch sample consisted
of previously GWAS genotyped 786 Dutch sIA cases (Yasuno
2010), and the 3,110 controls were recruited as part of the
Nijmegen Biomedical Study (n= 1,832) and the Nijmegen Bladder
Cancer Study (n = 1,278) [53,54]. The relevant medical ethical
committees approved all studies and all participants provided
written informed consent.
The patients were admitted to the Utrecht University Medical
Center between 1997 and 2007. The sIA-SAH cases were verified
with CT scan and sIAs by angiography. Unruptured sIAs were
identified by angiography in the absence of clinical or radiological
signs of SAH [12]. Patients reporting at least 1 first-degree relative
carrying sIA disease were considered familial.
The Nijmegen Biomedical Study is a population based cross-
sectional study conducted by the Radboud University Nijmegen
Medical Centre [53,54]. Age and sex stratified, randomly selected
adults ($18 years) of Nijmegen (n = 22,452) received an invitation
to fill out a postal questionnaire on lifestyle and medical history.
The following cases and controls were excluded: missingness $
0.05 (n= 10); IBD$0.2 (n = 102); heterozygosity ./,3 standard
deviations from the mean (n = 46); and principal component
analysis outliers (n = 43). The intersection of SNPs in different
platforms was first extracted and symmetric SNPs were removed
(A/T, C/G). SNPs prior to the imputation were filtered by the
following QC criteria: genotype missingness .0.05; MAF,0.01;
HWE p,0.001; differential missingness between cases and
controls p,1E-5.
The final Dutch replication sample consisted of 717 cases and
3,004 controls (Table 1).
Replication strategy
From both of the analyses (the case vs. controls and the number
of sIAs) the best independent SNPs were taken to replication if p,
5E-6. Additional significant independent SNPs in a locus was
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tested by analyzing each SNP within 1 MB from the top SNP
while adding the top SNP as a covariate. Additionally the most
significant SNP in the current study in 2q33.1 region with
uncertain evidence in previous sIA GWASs was taken to
replication. Variant was considered replicated if it reached one-
tailed significance of p,0.05 and was consistent in terms of risk
allele. In all of the results, one-tailed p-values are given for the
Finnish replication and in Dutch results.
Genotyping
Genomic DNA was extracted from peripheral blood and
genotyped by Illumina arrays: the Finnish discovery sample and
the Dutch replication cases by CNV370k DUO chip; the HBCS
and YFS controls by Illumina Human670K customBeadChip; and
the H2000 controls by Illumina Infinium HDHuman610-Quad
BeadChip.
In the Finnish replication sample, DNA was genotyped using
Sequenom MassARRAY system and iPLEX Gold assays (Seque-
nom Inc., San Diego, USA). The data was collected using the
MassARRAY Compact System (Sequenom) and the genotypes
were called using TyperAnalyzer software (Sequenom). Genotyp-
ing quality was examined by a detailed QC procedure consisting
of success rate checks, duplicates, water controls and Hardy-
Weinberg Equilibrium (HWE) testing. SNPs were filtered if
genotype missingness .0.05 or if HWE p,0.001.
Imputation
For imputation of additional genotypes in the discovery sample,
the Young Finns replication cohort and in the 2nd Dutch replication
sample the genotypes were first pre-phased [55] using the Shape-IT
[56] phasing software and the pre-phased haplotypes were subjected
to imputation. The Impute version 2.2.2 software [57] with 1,000
Genomes Phase I integrated variant set release (v3) reference panel
(05 Mar 2012 release downloaded from http://mathgen.stats.ox.ac.
uk/impute/data_download_1000G_phase1_integrated.html) was
used. Imputed genotypes were filtered if the Impute info measure
was ,0.5 or minor allele frequency ,0.01 in the Finnish discovery
sample.
eQTL analysis
We analyzed whether the identified genome-wide significant
SNPs might affect gene expression by using the European samples
of the Geuvadis RNA-sequencing data set, with mRNA sequenc-
ing data from LCLs of 373 samples from the FIN, CEU, GBR and
TSI populations of 1000 Genomes project (for details, see [21]).
We did eQTL analysis for each of the associating variants and
all the genes within a 1 MB window that were expressed in .50%
of the individuals (Table eQTL). We used exon quantifications
based on individual read counts per exon, after correction by the
total number of mapped reads per sample and PEER normali-
zation to remove technical variation. For each exon, we calculated
linear regression between these expression values and genotype
dosage of the associating variants in the 1000 Genomes data.
Regional association plots
Regional association plots were generated using LocusZoom
with LD data from European populations of 1000 Genomes
project (Hg19/March 2012) [58].
Search of regulatory elements at identified variants
The UCSC Genome Browser and HaploReg version 2 [19]
were used to search for ENCODE regulatory element regions
located at the five genome-wide significant variants. HaploReg
database also annotates if SNP resides on a putative transcription-
factor binding site (TFBS) according to Transfac or Jaspar TFBS
profiles and also 10 most enriched TFBS profiles identified in
ENCODE TF Chip-Seq peaks. We used all the Jaspar and
Transfac annotations and three most enriched ENCODE based
TFBS annotations for each TF.
Statistical analysis
GWA was performed against two complementary phenotypes:
the case vs. control status and the number of sIAs.
Case vs. control analysis. SNPTEST v2.3.0 was used for
the association analysis, assuming additive effect. Genotype
uncertainty in the imputed SNPs was taken in to account by
treating them as continuous expected genotype dosages. The
gender was used as a covariate.
Aneurysm count analysis. The Vuong test [59] showed that
the negative binomial model was a significantly better fit to the sIA
count per individual when compared to the Poisson model. The
zero-inflated negative binomial model was not significantly better
either, so the simpler negative binomial model (glm.nb function in
MASS R package) was used. When assessing the model fits, the
gender was used as a predictor. Imputation uncertainty was taken
in to account by treating the imputed SNPs as continuous
expected genotype dosages, and the gender was used as a
covariate.
Meta-analysis. The association evidence from the discovery
and replication samples were combined by inverse variance-
weighted fixed-effects meta-analysis, using Plink v.1.07 [49].
Heterogeneity statistic I2 and confidence intervals were calculated
according to Higgins et al. [60] using metafor R package [61].
Genome-wide significance level estimation. As the stan-
dard genome-wide significance value of 5 * 1028 is estimated to
correct for independent tests when testing all common variants
(MAF.=5%). As we tested variants with MAF.=1%, the
standard genome-wide significance may be liberal. A simple
Bonferroni correction would be much too string because of
correlation between tested variants.
We estimated approximately independent number of variants
by analysing chromosomes 1 and 7 of European individuals of the
1000 Genomes Project. We pruned the set of variants to be
approximately independent (pairwise r2,=0.6 within 250 kb of
each other) using WDIST (https://www.cog-genomics.org/wdist/).
This resulted in 308547 and 358834 independent variants out of
2215231 and 2553047 respectively. Taking the same proportion
(14%) of SNPs from the 9 359 231 variants in the discovery is
1 303 594 variants which yields genome-wide significance of 3.82 *
10-8. We similarly estimated squared correlation r2 of the 528677
genotyped and imputed variants of all 3273 discovery samples in
chromosome 7 using custom Python script. The proportion of
approximately independent variants was 53 909 (10.2%), which is
lower than in the full set of 1000 Genomes variants (threshold 5.2 *
10-8).
Heritability analysis. The fraction of additive genetic
variance explained by the five identified loci was estimated using
the liability threshold model [62]. The model assumes an additive
effect at each locus, which shifts the mean of a normally distributed
distribution of disease liability for each genotype. The combined
genetic variance explained by the five SNPs (rs74972714,
rs113816216, rs7501821, rs1509275133, rs12472355) in the five
loci was assumed to be the sum of variances explained by each SNP.
Risk allele frequencies in controls and OR’s from combined Finnish
samples was used and population prevalence of 3% of the sIA
disease was assumed [1]. Heritability of the six previously identified
lead SNPs (rs9298506, rs1333040, rs12413409, rs9315204,
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rs11661542, rs6841581) was estimated using the allele frequencies
and effect sizes from the discovery cohort of the current study.
Supporting Information
Figure S1 Quantile-quantile plot of case vs. control analysis.
(TIF)
Figure S2 Quantile-quantile plot of aneurysm count analysis.
(TIF)
Figure S3 Manhattan plot of case versus control analysis.
(TIFF)
Figure S4 Manhattan plot of aneurysm count analysis.
(TIFF)
Figure S5 Pairwise plot of eQTL association statistics vs.
aneurysm association statistics in the discovery cohort. All variants
within 1 MB of reported variants and with both eQTL and
aneurysm data available are plotted. Nominal aneurysm associa-
tion p-value threshold of p= 0.05 is shown as vertical line.
(TIF)
Figure S6 Regional eQTL association landscape of the five
identified saccular intracranial aneurysm loci. The reported lead
SNP association to sIA disease is shown as purple circle. All other
data points are eQTL association p-values (only association p-
values,0.001 are shown). Color coding indicates LD between the
sIA variant and each eQTL variant. Association p-values (2log10
scale, y-axis) of variants are shown according to their chromo-
somal positions (x-axis). Blue lines indicate the genetic recombi-
nation rate (cM/Mb). Figures A–C present the loci identified in
the case vs. control analysis at 2q23.3, 5q31.3, and 6q24.2,
respectively. Figure D presents the 7p22.1 locus associated to the
sIA count per patient. Figure E presents the 2q33.1 locus with
inconclusive previous evidence.
(TIF)
Table S1 All variants analyzed in case vs. control analysis in the
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Table S2 All variants analyzed in the aneurysm count analysis in
the discovery and the replication phases.
(XLS)
Table S3 Genotype to aneurysm count distribution of genome-
wide significant rs150927513 in combined Finnish discovery and
replication cohorts.
(XLS)
Table S4 Regulatory elements at the identified variants.
(XLS)
Table S5 Previous GWAS studies of the sIA disease. Association
results are reported according to chromosomal loci and differing
SNP is indicated above each study column if different from
primary study. Each cell reports [odds ratio; (pvalue); risk allele;
allele frequency in controls] (e.g 1.6 (4.5E-4) 38%) unless otherwise
noted.
(XLS)
Table S6 eQTL analysis results of correlating each genome-
wide significant SNP to exon expression levels of genes ,=1 MB
away from the index SNP.
(XLS)
Table S7 Imputation accuracy statistics of all genome-wide
significant variants.
(XLS)
Table S8 Genotyping of 87 individuals of the discovery sample
by direct genotyping.
(XLS)
Table S9 Heterogeneity statistics of meta-analysis combining all
three samples.
(XLS)
Table S10 All variants with eQTL associations p,0.001 and
aneurysm association (discovery sample) p,0.05 within 1 MB of
reported variants.
(XLS)
Table S11 Validation of imputed genotypes by Sanger sequenc-
ing.
(XLS)
Table S12 Putative protein product function affecting variants
within 1 MB of the identified variants in 583 whole exome
sequenced Finnish individuals.
(XLS)
Table S13 In silico validation of genotype imputation accuracy
in Dutch population using 96 individuals with both genotype chip
data and high coverage(.406on average) full genome sequencing
data available.
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positive probabilities due to imputation inaccuracy.
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